Brief Report: Contralateral Lobectomy for Second Primary NSCLC: Perioperative and Long-Term Outcomes.
Brief Report: Contralateral Lobectomy for Second Primary NSCLC: Perioperative and Long-Term Outcomes.
复制标题
DOI：
10.1016/j.jtocrr.2022.100362
复制
发表时间：
2022-08
影响因子：
--
通讯作者：
Adusumilli, Prasad S.
中科院分区：
文献类型：
--
作者：
Choe, Jennie K.;Zhu, Amy;Byun, Alexander J.;Zheng, Junting;Tan, Kay See;Dycoco, Joe;Bains, Manjit S.;Bott, Matthew J.;Downey, Robert J.;Huang, James;Isbell, James M.;Molena, Daniela;Rusch, Valerie W.;Park, Bernard J.;Rocco, Gaetano;Sihag, Smita;Jones, David R.;Adusumilli, Prasad S.
解剖切除术-通常通过肺叶切除术-是早期NSCLC患者的标准治疗方法。随着早期非小细胞肺癌患者的诊断率、生存率和患病率的提高，第二原发性非小细胞肺癌的发生率以及因此对异时性癌症进行对侧肺叶切除术的需求正在增加。对侧肺叶切除术后的围手术期结局未知。在1995年至2020年期间接受对侧肺叶切除术治疗第二原发性NSCLC的患者中，我们评估了90天死亡率和主要发病率（Clavien-Dindo 3-5级）及其与临床病理变量的相关性，包括对侧肺叶切除术的年份和肺叶切除术之间的持续时间。共有98例患者因第二原发性NSCLC接受对侧肺叶切除术; 51例在早期（1995-2009），47例在晚期（2010-2020）。对侧肺叶切除术后有5例死亡，23例患者发生重大疾病;与1995年至2009年相比，2010年至2020年的死亡率均有所下降（死亡率10%-0%，重大疾病35%-11%）。主要发病率与肺叶切除间隔时间小于1年、肺一氧化碳弥散量<80%和右下叶切除相关。死亡率与鳞状细胞癌相关。I期NSCLC行对侧肺叶切除术的患者3年总生存率为74%（95%置信区间：64%-85%），3年肺癌累积死亡率为15%（95%置信区间：6.5%-24%）。在2010年之前，第二原发早期NSCLC患者的同侧肺叶切除术与不良结局相关。自2010年以来，对侧肺叶切除术的围手术期和长期结局与单侧肺叶切除术后报告的结局相当。
Anatomical resection—often by lobectomy—is the standard of care for patients with early stage NSCLC. With increased diagnosis, survival, and prevalence of persons with early stage NSCLC, the incidence of second primary NSCLC, and consequently, the need for contralateral lobectomy for a metachronous cancer, is increasing. Perioperative outcomes after contralateral lobectomy are unknown. Among patients who underwent contralateral lobectomy for second primary NSCLC during 1995 to 2020, we evaluated 90-day mortality and major morbidity (Clavien-Dindo grades 3–5) rates and their association with clinicopathologic variables, including the year of contralateral lobectomy and duration between lobectomies. A total of 98 patients underwent contralateral lobectomy for second primary NSCLC; 51 during an early time period (1995–2009) and 47 from a late time period (2010–2020). There were five mortalities and 23 patients with major morbidities after contralateral lobectomy; both rates decreased in 2010 to 2020 compared with 1995 to 2009 (mortality 10%–0%, major morbidity 35%–11%). Major morbidity was associated with an interval of less than 1 year between lobectomies, a diffusing capacity of the lung for carbon monoxide <80%, and right lower lobe resections. Mortality was associated with squamous cell carcinoma. Patients who underwent contralateral lobectomy for stage I NSCLC had 74% (95% confidence interval: 64%–85%) 3-year overall survival and 15% (95% confidence interval: 6.5%–24%) 3-year lung cancer cumulative incidence of death. Contralateral lobectomy for second primary early stage NSCLC was associated with poor outcomes before 2010. Since 2010, perioperative and long-term outcomes of contralateral lobectomy have been comparable with reported outcomes after unilateral lobectomy.
登录
查看更多内容
影响因子：
28.4
作者：
Ganti, Apar Kishor;Klein, Alyssa B.;Chou, Engels
通讯作者：
Chou, Engels
影响因子：
9
作者：
Dindo, D;Demartines, N;Clavien, PA
通讯作者：
Clavien, PA
影响因子：
6
作者：
Keshava, Hari B.;Tan, Kay See;Dycoco, Joe;Huang, James;Berkowitz, Alison;Sumner, Dyana;Devigne, Amy;Adusumilli, Prasad;Bains, Manjit;Bott, Matthew;Isbell, James;Downey, Robert;Molena, Daniela;Park, Bernard;Rocco, Gaetano;Sihag, Smita;Jones, David R.;Rusch, Valerie W.
通讯作者：
Rusch, Valerie W.
非小细胞肺癌患者阶段转移和人口死亡率的关联。
影响因子：
13.8
作者：
Flores R;Patel P;Alpert N;Pyenson B;Taioli E
通讯作者：
Taioli E
影响因子：
1.5
作者：
Hattori, Aritoshi;Suzuki, Kenji;Oh, Shiaki
通讯作者：
Oh, Shiaki